Tumor Infiltrating Lymphocytes with Injected IL-2 vs Membrane Bound IL-2

TIL therapies have shown potential for impact across multiple solid tumors. One challenge, however, is the use of IL-2 administration to support TIL function. Our latest #HowCellsWork story illustrates this challenge and potential solutions that could improve patient outcomes.
Posted February 5, 2022 · Follow Us:
Share: